Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Genzyme

- PMLiVE

Sanofi extends growth spurt thanks to Genzyme, Dupixent

US approval of Cablivi adds to good news

- PMLiVE

Sanofi gets US okay for $270,000 blood disorder drug Cablivi

First in a new class of single-domain antibody fragments drugs

Six factors that drive a multiple sclerosis patient’s choice of disease-modifying therapy

MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget.

Blue Latitude Health

- PMLiVE

Sanofi’s Darzalex rival scores in myeloma trial

Antibody first to show benefit in combination setting

- PMLiVE

GSK and Sanofi join Finland’s 500,000 genomics study

AstraZeneca, MSD and Pfizer already participating

Innovative approaches in the treatment of multiple sclerosis

Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.

Blue Latitude Health

Sanofi reception

Sanofi and Regeneron re-jig immuno-oncology deal

Partners refocus around two promising bispecific candidates

Living my best life with multiple sclerosis

Multi-award-winning advocate and patient engagement champion Trishna Bharadia gives a valuable insight into life with multiple sclerosis. She explains how treatment has changed, how our healthcare systems and pharma can...

Blue Latitude Health

- PMLiVE

As France protests, Sanofi takes axe to 670 jobs

Layoffs latest in restructuring programme

- PMLiVE

CHMP backs Sanofi’s all-oral sleeping sickness drug

Sanofi's drug and others given green light by EMA committee

- PMLiVE

Three key development areas in the management of multiple sclerosis

Last month, Mark Walker, our business development director, and Fabrice Allum, managing director of Porterhouse Insights, attended the ECTRIMS (European Committee for treatment and research in multiple sclerosis) congress in...

Porterhouse Medical Group

Sanofi reception

Dupixent helps put Sanofi back on growth track

French drugs giant sees an 8% rise in vaccine sales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links